

Notice of Allowability	Application No.	Applicant(s)	
	10/523,014	YANNONI ET AL.	
	Examiner	Art Unit	
	Maryam Monshipouri	1656	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to _____.
2. The allowed claim(s) is/are 70-75.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application
6. Interview Summary (PTO-413),
Paper No./Mail Date 11/15/07.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this Examiner's Amendment was given in a telephone interview with , Mr. J. P. Kastenmayer on 11/15//2007.

Examiner's Amendment to the Claims

Cancel claims 1-69 and 76-77.

In claim 70, lines 4-6, after "MK2 polypeptide", delete ", wherein said MK2 polypeptide comprises a proline-rich region, a kinase catalytic domain, a threonine residue that can be phosphoporylated by MAP kinase, and a nuclear localization signal;"

In claim 70, line 8, after "comprising", insert --- a Shc polypeptide set forth as ---.

Examiner's Amendments to the Specification

In page 1, paragraph [001], line, 1, after "this application", insert --- is a 371 of international application PCT/US03/23981, filed 8/1/2003, which ---.

In page 1, paragraph [001], line 2, after "60/400,044" insert --- filed 8/2/2002 ---.

The following is an **Examiner's Statement of Reasons for Allowance:**

Claims 70-75 are directed to a yeast two hybrid screening assay comprising providing an assay system comprising first fusion protein comprising an MK2

Serial Number:10/523,014
Art Unit 1656

polypeptide (see figure 2 of Stokoe et al., Biochem. J., 296, 843-849, 1993, cited in the specification and the IDS) and a second fusion protein comprising Shc protein of a specific amino acid sequence, measuring a level of interaction between the fusion proteins in the presence and absence of a test compound and comparing the level of interaction of the fusion proteins wherein difference in the amount of complex in the presence of the test compound relative to the amount of complex in the absence of test compound indicates that the test compound inhibits or promotes complex formation.

Claimed Shc protein, amino acid sequence is free of prior art. Further the prior art does not teach or suggest preparing such specifically claimed amino acid sequence. Hence said sequence is also non-obvious. Since said amino acid sequence is both novel and non-obvious a method of use of said amino acid sequence in a two hybrid screening assay as claimed is also novel and non-obvious.

Claims 70-75 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maryam Monshipouri whose telephone number is (571) 272-0932. The examiner can normally be reached on Tues.-Fri., from 7:00 a.m to 5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr Bragdon can be reached on (571) 272-0931. The fax phone

Serial Number:10/523,014
Art Unit 1656

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

M. Monshpouri
Maryam Monshipouri Ph.D.

Primary Examiner
